cp 115953 has been researched along with ciprofloxacin in 3 studies
| Studies (cp 115953) | Trials (cp 115953) | Recent Studies (post-2010) (cp 115953) | Studies (ciprofloxacin) | Trials (ciprofloxacin) | Recent Studies (post-2010) (ciprofloxacin) |
|---|---|---|---|---|---|
| 20 | 0 | 0 | 16,060 | 1,331 | 6,092 |
| Protein | Taxonomy | cp 115953 (IC50) | ciprofloxacin (IC50) |
|---|---|---|---|
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | 0.41 | |
| DNA gyrase subunit B | Bacillus subtilis subsp. subtilis str. 168 | 6.3 | |
| DNA gyrase subunit A | Bacillus subtilis subsp. subtilis str. 168 | 6.3 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.31 | |
| DNA gyrase subunit B | Staphylococcus aureus | 4.32 | |
| DNA gyrase subunit A | Escherichia coli K-12 | 0.6845 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 0.5632 | |
| DNA topoisomerase 4 subunit B | Staphylococcus aureus | 6.485 | |
| DNA topoisomerase 4 subunit A | Staphylococcus aureus | 4.8011 | |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.41 | |
| DNA gyrase subunit A | Staphylococcus aureus | 4.32 | |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | 0.41 | |
| DNA topoisomerase 4 subunit A | Bacillus subtilis subsp. subtilis str. 168 | 1.7 | |
| DNA topoisomerase 4 subunit B | Bacillus subtilis subsp. subtilis str. 168 | 1.7 | |
| GABA theta subunit | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | 0.41 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Burden, DA; Elsea, SH; Lomenick, JP; Osheroff, N; Westergaard, M | 1 |
| Anderson, VE; Gootz, TD; Kaczmarek, FS; Osheroff, N; Zaniewski, RP | 1 |
3 other study(ies) available for cp 115953 and ciprofloxacin
| Article | Year |
|---|---|
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Topics: Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; CHO Cells; Ciprofloxacin; Cricetinae; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Electrophoresis, Agar Gel; Enzyme Activation; Etoposide; Fluoroquinolones; Genistein; Isoflavones; Kinetics; Molecular Structure; Quinolones | 1997 |
Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
Topics: Anti-Infective Agents; Biological Evolution; Ciprofloxacin; DNA Damage; DNA Repair; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Escherichia coli; Etoposide; Fluoroquinolones; Gram-Positive Bacteria; Kinetics; Quinolones; Staphylococcus aureus | 1999 |